Lawrence E. Morris

4.2k citations

122 papers · 2.8k indexed · h-index 23

Impact in

Hematology top 0.2%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
Transplantation top 1%
- Renal Transplantation Outcomes and Treatments

Papers in ⓘ

Hematology 100
- Hematopoietic Stem Cell Transplantation 76
- Acute Myeloid Leukemia Research 38
- Multiple Myeloma Research and Treatments 10
Transplantation 18
- Renal Transplantation Outcomes and Treatments 18

Co-authors: Asad Bashey (87 shared papers)Scott R. Solomon (86 shared papers)H. Kent Holland (81 shared papers)Stacey Brown (32 shared papers)Xu Zhang (29 shared papers)Connie A. Sizemore (25 shared papers)Melhem Solh (56 shared papers)Melissa Sanacore (13 shared papers)
Journals: Blood (47 papers)Biology of Blood and Marrow Transplantation (27 papers)Bone Marrow Transplantation (11 papers)Transplantation and Cellular Therapy (7 papers)Blood Advances (5 papers)
Partner nations: United States Netherlands Belgium

In The Last Decade

Lawrence E. Morris

115 papers receiving 2.7k citations

Peers

Countries citing papers authored by Lawrence E. Morris

Since Specialization

Citations

This map shows the geographic impact of Lawrence E. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence E. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence E. Morris more than expected).

Fields of papers citing papers by Lawrence E. Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence E. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence E. Morris. The network helps show where Lawrence E. Morris may publish in the future.

Co-authors

The 25 scholars most cited alongside Lawrence E. Morris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lawrence E. Morris Line = papers co-authored together Lawrence E. Morris links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation Journal of Clinical Oncology ·Asad Bashey, Xu Zhang, Connie A. Sizemore, Karen Manion, Stacey Brown, H. Kent Holland, Lawrence E. Morris, Scott R. Solomon	2013	333
2	CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation Blood ·Asad Bashey, Bridget Medina, Sue Corringham, Mildred Pasek, Ewa Carrier, Linda Vrooman, Israel Lowy, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, James R. Mason, Edwin P. Alyea, Robert J. Soiffer, Edward D. Ball	2008	270
3	Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial Biology of Blood and Marrow Transplantation ·Scott R. Solomon, Connie A. Sizemore, Melissa Sanacore, Xu Zhang, Stacey Brown, H. Kent Holland, Lawrence E. Morris, Asad Bashey	2012	207
4	Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome Biology of Blood and Marrow Transplantation ·Yvette L. Kasamon, Leo Luznik, Mary S. Leffell, Jeanne Kowalski, Hua-Ling Tsai, Javier Bolaños‐Meade, Lawrence E. Morris, Pamela Crilley, Paul V. O’Donnell, Nancy Rossiter, Carol Ann Huff, Robert A. Brodsky, William Matsui, Lode J. Swinnen, Ivan Borrello, Jonathan D. Powell, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs	2009	191
5	Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias Clinical Cancer Research ·Judith E. Karp, Ivana Gojo, Роберто Пили, Christopher D. Gocke, Jacqueline M. Greer, Chuanfa Guo, David Z. Qian, Lawrence E. Morris, Michael Tidwell, Helen Chen, James A. Zwiebel	2004	143
6	A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia Blood ·Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib, Eric J. Feldman, Jacqueline M. Greer, Jane L. Liesveld, Laura M. Bruzek, Lawrence E. Morris, Youn Park, Alex A. Adjei, Scott H. Kaufmann, Elizabeth Garrett‐Mayer, Peter L. Greenberg, James R. Wright, Judith E. Karp	2006	129
7	Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors Biology of Blood and Marrow Transplantation ·Scott R. Solomon, Connie A. Sizemore, Melissa Sanacore, Xu Zhang, Stacey Brown, H. Kent Holland, Lawrence E. Morris, Asad Bashey	2015	112
8	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial Blood ·Ephraim J. Fuchs, Paul V. O’Donnell, Mary Eapen, Brent R. Logan, Joseph H. Antin, Peter Dawson, Steven M. Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein	2020	106
9	Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index Biology of Blood and Marrow Transplantation ·Asad Bashey, Xu Zhang, Katelin C Jackson, Stacey Brown, Michelle Ridgeway, Melhem Solh, Lawrence E. Morris, H. Kent Holland, Scott R. Solomon	2015	105
10	A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia Blood ·Mitch Raponi, Jeffrey E. Lancet, Hongtao Fan, Lesley Dossey, Grace Lee, Ivana Gojo, Eric J. Feldman, Jason Gotlib, Lawrence E. Morris, Peter L. Greenberg, James R. Wright, Jean‐Luc Harousseau, Bob Löwenberg, Richard M. Stone, Peter De Porre, Yixin Wang, Judith E. Karp	2007	98
11	A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders Leukemia Research ·Judith E. Karp, Francis J. Giles, Ivana Gojo, Lawrence E. Morris, Jacqueline M. Greer, Bonny Johnson, Mya Thein, Mario Sznol, Jennifer A. Low	2007	92
12	Infliximab for steroid‐refractory acute GVHD: A case series American Journal of Hematology ·David A. Jacobsohn, Jason P. Hallick, Viki Anders, Stephanie McMillan, Lawrence E. Morris, Georgia B. Vogelsang	2003	72
13	Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia Journal of Clinical Oncology ·Steven D. Gore, Ivana Gojo, Mikkael A. Sekeres, Lawrence E. Morris, Marcel P. Devetten, Katarzyna Jamieson, Robert L. Redner, R.J. Arceci, Ibitayo Owoeye, Tianna Dauses, Esther Schachter-Tokarz, Robert E. Gallagher	2010	69
14	Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables Biology of Blood and Marrow Transplantation ·Scott R. Solomon, Michael T. Aubrey, Xu Zhang, Allison Piluso, Brian M. Freed, Stacey Brown, Katelin C Jackson, Lawrence E. Morris, H. Kent Holland, Melhem Solh, Asad Bashey	2018	61
15	Extramedullary acute myelogenous leukemia Blood Reviews ·Melhem Solh, Scott R. Solomon, Lawrence E. Morris, Kent Holland, Asad Bashey	2016	45
16	Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation Biology of Blood and Marrow Transplantation ·Scott R. Solomon, Melissa Sanacore, Xu Zhang, Stacey Brown, Kent Holland, Lawrence E. Morris, Asad Bashey	2014	41
17	Tipifarnib (ZARNESTRATM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial. Blood ·Jeffrey E. Lancet, Jason Gotlib, Ivana Gojo, Eric J. Feldman, Lawrence E. Morris, Alain Thibault, Jane L. Liesveld, Jacqueline M. Greer, Kathleen Dugan, Mitch Raponi, James R. Wright, Peter L. Greenberg, Judith E. Karp	2004	39
18	Factors Predicting Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center Biology of Blood and Marrow Transplantation ·Melhem Solh, Xu Zhang, Katelin Connor, Stacey Brown, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, Asad Bashey	2016	38
19	Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial Bone Marrow Transplantation ·Scott R. Solomon, Connie A. Sizemore, X Zhang, Stacey Brown, H. Kent Holland, Lawrence E. Morris, Asad Bashey	2014	33
20	Outpatient myeloablative allo-SCT: a comprehensive approach yields decreased hospital utilization and low TRM Bone Marrow Transplantation ·Scott R. Solomon, R H Matthews, Amy M. Barreras, Asad Bashey, Karen Manion, Kathy McNatt, Dawn Speckhart, D G Connaghan, Lawrence E. Morris, H. Kent Holland	2009	31

About Lawrence E. Morris

Lawrence E. Morris is a scholar working on Hematology, Transplantation, Oncology, Immunology and Genetics, having authored 122 papers that have together received 2.8k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (76 papers), Acute Myeloid Leukemia Research (38 papers), Acute Lymphoblastic Leukemia research (20 papers), Polyomavirus and related diseases (18 papers), Renal Transplantation Outcomes and Treatments (18 papers), T-cell and B-cell Immunology (17 papers), Immune Cell Function and Interaction (15 papers) and Multiple Myeloma Research and Treatments (10 papers). The work is most often cited by research in Hematology (2.2k citations), Transplantation (257 citations), Immunology (993 citations), Oncology (962 citations) and Genetics (266 citations). Lawrence E. Morris has collaborated with scholars based in United States, Netherlands and Belgium. Frequent co-authors include Asad Bashey, Scott R. Solomon, H. Kent Holland, Stacey Brown, Xu Zhang, Connie A. Sizemore, Melhem Solh, Melissa Sanacore, Karen Manion and Ivana Gojo. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, Transplantation and Cellular Therapy and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact